Urothelial Cancer | Specialty

The OncLive Urology condition center page is a comprehensive resource for clinical news and expert insights on urologic cancers, including prostate cancer, bladder cancer, testicular cancer, penile cancer, and renal cell carcinoma. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

IDE397 Plus Sacituzumab Govitecan Elicits Responses in MTAP-Deletion Urothelial Cancer

September 15th 2025

IDE397 plus sacituzumab govitecan shows preliminary efficacy in MTAP-deletion urothelial cancer.

Five Under 5: Top Oncology Videos for the Week of 9/7

September 14th 2025

The top 5 OncLive TV videos of the week cover insights in lung cancer, non–muscle-invasive bladder cancer, and colorectal cancer.

The OncFive: Top Oncology Articles for the Week of 9/7

September 13th 2025

The FDA has approved TAR-200 in urothelial cancer and selumetinib in pediatric NF-1–associated inoperable plexiform neurofibromas, and more.

Dr Jacob on the FDA Approval of the Gemcitabine Intravesical System for NMIBC

September 11th 2025

Joseph Jacob, MD, MCR, discusses the FDA approval of the gemcitabine intravesical system for patients with BCG-unresponsive NMIBC with carcinoma in situ.

Dr Necchi on the Design of the Phase 2 SURE-02 Study Assessing Pembrolizumab/Sacituzumab Govitecan in Muscle-Invasive Bladder Cancer

September 10th 2025

Andrea Necchi, MD, discusses the design of the SURE-02 study evaluating pembrolizumab plus sacituzumab govitecan in muscle-invasive bladder cancer.

FDA Approves TAR-200 in BCG-Unresponsive NMIBC With CIS

September 9th 2025

The FDA approved TAR-200 in patients with BCG-unresponsive NMIBC with carcinoma in situ, with or without papillary tumors.

Dr Sfakianos on Addressing Unmet Needs With Intravesical Mitomycin in Recurrent, Low-Grade, Intermediate-Risk NMIBC

September 5th 2025

John P. Sfakianos, MD, discusses the rationale for evaluating mitomycin intravesical solution in recurrent, low-grade, intermediate-risk NMIBC.

FDA Approval Is Sought for PredicineCARE Assay as Companion Diagnostic in Bladder Cancer

September 3rd 2025

The first part of a PMA seeking the approval of PredicineCARE as a companion diagnostic in bladder cancer was submitted to the FDA.

Dr Arafat on Evolving Neoadjuvant Treatment Strategies in MIBC

August 29th 2025

Waddah Arafat, MD, discusses how the use of neoadjuvant chemotherapy in MIBC has changed relative to the addition of immunotherapy to this paradigm.

Perioperative Pembrolizumab/Sacituzumab Govitecan May Provide Effective Alternative to Cystectomy in MIBC

August 29th 2025

Andrea Necchi, MD, discusses how initial findings from the SURE-02 study indicate the potential for bladder preservation over cystectomy in MIBC.

Dr Necchi on Molecular Data With Perioperative Sacituzumab Govitecan Plus Pembrolizumab in MIBC

August 28th 2025

Andrea Necchi, MD, discusses biomarker data with perioperative sacituzumab govitecan plus pembrolizumab in cisplatin-ineligible MIBC.

Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab Followed By Pembrolizumab Maintenance Demonstrates Efficacy in MIBC

August 27th 2025

Neoadjuvant sacituzumab govitecan plus pembrolizumab with adjuvant/maintenance pembrolizumab led to high cCR rates in MIBC.

UGN-102 Redefines Treatment Standards for Low-Grade, Intermediate-Risk NMIBC

August 27th 2025

William C. Huang, MD, discusses the FDA approval of UGN-102 for the treatment of patients with recurrent, low-grade, intermediate-risk NMIBC.

Dr Bedke on Advice for Using Enfortumab Vedotin/Pembrolizumab in Previously Untreated Advanced Urothelial Carcinoma

August 26th 2025

Jens Bedke, MD, discusses considerations for using enfortumab vedotin plus pembrolizumab in the frontline setting for advanced urothelial carcinoma.

The OncFive: Top Oncology Articles for the Week of 8/17

August 23rd 2025

Adjuvant atezolizumab boosts survival in bladder cancer, FDA clears companion diagnostic for nivolumab doublet in MSI-H/dMMR colorectal cancer, and more.

Gene Therapy Efficacy and Safety Considerations May Refine BCG-Unresponsive NMIBC Management

August 22nd 2025

Alberto Martini, MD, discusses the safety of intravesical therapies in NMIBC, the efficacy of EG-70, and future trial needs in this population.

Pivotal Study Data Support Further Research in BCG-Unresponsive, High-Risk NMIBC

August 21st 2025

Alberto Martini, MD discusses how systemic treatment approaches and key trials have refined care for patients with BCG-unresponsive NMIBC.

Alpha1H Demonstrates Clinical Benefit in NMIBC

August 21st 2025

Alpha1H met all primary and secondary end points in a phase 2 study in non–muscle-invasive bladder cancer.

Dr Powles on the Role of the CREST Study in Future Clinical Trial Design in BCG-Naive NMIBC

August 21st 2025

Thomas Powles, MBBS, MRCP, MD, discusses how future clinical trials could leverage the CREST trial as a basis for BCG-naive NMIBC treatment development.

Dr Martini on the Clinical Significance of Nadofaragene Firadenovec in BCG–Unresponsive NMIBC

August 20th 2025

Alberto Martini, MD, discusses the current optimal role of nadofaragene firadenovec in the BCG-unresponsive NMIBC treatment paradigm.